Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis

Published:2021-06 Issue: Volume:57 Page:5-17
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Salvo Elizabeth M.^ORCID,Ramirez Abril Oliva,Cueto Jenilee^ORCID,Law Ernest H.^ORCID,Situ Aaron,Cameron Chris^ORCID,Samjoo Imtiaz A.^ORCID

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference53 articles.

1. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

2. Breast cancer statistics, 2019. CA;DeSantis;Canc J Clinic,2019

3. Breast cancer treatment: a review;Waks;Jama,2019

4. Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up;Yang;Breast Canc Res Treat,2019

5. Challenges in the treatment of triple negative and HER2-overexpressing breast cancer;Hoeferlin;J Surgery Sci,2013

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New treatment strategy for early hormone receptor-positive HER2-negative breast cancer: updated results of adjuvant abemaciclib trial in operable and locally advanced breast cancer;Medical alphabet;2024-09-08

2. Recurrence and associated factors of breast cancer among women in sub saharan africa, systematic review and meta-analysis;European Journal of Surgical Oncology;2024-09

3. Adjuvant and Neoadjuvant Therapy for Breast Cancer: A Systematic Review;European Journal of Breast Health;2024-07-01

4. Real-world data of HER2-negative early breast cancer patients treated with anthracycline and/or taxane regimens in Japan;Breast Cancer;2024-04-29

5. Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials;Journal of Personalized Medicine;2024-04-27